Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Early-Stage and Operable Non-Small Cell Lung Cancer Treatment: Current Practice...
share announcement

Early-Stage and Operable Non-Small Cell Lung Cancer Treatment: Current Practice and Future Perspectives

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: 20 May 2025 | Viewed by 3049

Special Issue Editors

Dr. Francisco Aécio Almeida

E-Mail Website
Guest Editor
Department of Pulmonary Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH 44195, USA
Interests: bronchoscopy; lung cancer; lung nodules; malignant mesothelioma
Dr. Debora S. Bruno

E-Mail Website
Guest Editor
Division of Hematology and Oncology, Case Western Reserve University Hospitals/Seidman Cancer Center, Cleveland, OH 44106, USA
Interests: lung cancer; disparities; biomarker testing; clinical trials

Special Issue Information

Dear Colleagues,

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths in the U.S. and globally. Over the last decade, however, incidence-based mortality rates have declined at accelerated rates, not only due to efforts in screening for detection of early-stage disease, but also due to remarkable advances in the treatment of metastatic NSCLC. These include the approval of checkpoint inhibitors and a variety of targeted therapies which require comprehensive biomarker testing.

Over the last 5 years, a multitude of clinical trials investigating the role of such therapies for the improvement of long-term survival of operable patients has come to fruition. With the approval of targeted therapy and checkpoint inhibitors, a fast-paced change in the standard of care has demanded an integrated and effective multidisciplinary care of patients with operable NSCLC.

This Special Issue will include narrative reviews on the current treatment, as well as future perspectives for the management of early-stage and operable patients with NSCLC, encompassing biomarker testing, advances in systemic therapy and surgical treatment, and their early rehabilitation.

Dr. Francisco Aécio Almeida
Dr. Debora S. Bruno
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • non-small cell lung cancer
  • biomarker testing
  • checkpoint inhibitors
  • perioperative therapy
  • targeted therapy
  • next-generation sequencing
  • radiation therapy
  • pulmonary rehabilitation in NSCLC

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

18 pages, 777 KiB  
Review
Pulmonary Rehabilitation in Patients with Operable Non-Small Cell Lung Cancer
by Jeffrey Zhong, Ilene Trinh, Shine Raju and Melinda Hsu
J. Clin. Med. 2025, 14(3), 770; https://doi.org/10.3390/jcm14030770 - 24 Jan 2025
Viewed by 1062
Abstract
Lung cancer is the leading cause of cancer-related death worldwide, and patients with operable early-stage NSCLC are typically managed surgically. While effective, surgical resection can significantly impact pulmonary function and quality of life. Pulmonary rehabilitation (PR) is a comprehensive, multimodal approach that is [...] Read more.
Lung cancer is the leading cause of cancer-related death worldwide, and patients with operable early-stage NSCLC are typically managed surgically. While effective, surgical resection can significantly impact pulmonary function and quality of life. Pulmonary rehabilitation (PR) is a comprehensive, multimodal approach that is an established cornerstone in the treatment of COPD. It has similarly demonstrated multiple benefits in patients with lung cancer who have undergone lobectomy or resection by improving pulmonary function, increasing exercise tolerance, improving nutritional status, providing psychological support, and enhancing quality of life. Despite this, PR for early-stage operable NSCLC is oftentimes not standardized, and challenges to adherence remain. In this review, we examine the components of PR, the role of PR in pre- and postoperative settings in patients with early-stage NSCLC, implementation strategies for PR, and future directions and challenges of PR in operable NSCLC. Full article
(This article belongs to the Special Issue Early-Stage and Operable Non-Small Cell Lung Cancer Treatment: Current Practice and Future Perspectives)
►▼ Show Figures

Figure 1

19 pages, 4085 KiB  
Review
The Treatment of Patients with Early-Stage Non-Small Cell Lung Cancer Who Are Not Candidates or Decline Surgical Resection: The Role of Radiation and Image-Guided Thermal Ablation
by David S. Buchberger, Rishabh Khurana, Michael Bolen and Gregory M. M. Videtic
J. Clin. Med. 2024, 13(24), 7777; https://doi.org/10.3390/jcm13247777 - 19 Dec 2024
Viewed by 1322
Abstract
The standard of care for early-stage NSCLC has historically been surgical resection. Given the association of lung cancer with smoking, a large number of early-stage patients also have active smoking-related medical comorbidities such as COPD precluding surgery. The current approach for treating such [...] Read more.
The standard of care for early-stage NSCLC has historically been surgical resection. Given the association of lung cancer with smoking, a large number of early-stage patients also have active smoking-related medical comorbidities such as COPD precluding surgery. The current approach for treating such inoperable patients is frequently considered to be stereotactic body radiation therapy (SBRT). SBRT (also known as stereotactic ablative radiation therapy or SABR) is a curative modality that precisely delivers very high dose radiation in few (typically <5) sessions. That said, because of their minimal invasiveness and repeatable nature, image-guided thermal ablation therapies such as radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation (CA) have also been used to treat early-stage lung tumors. For those patients deemed to have “high operative risk” (i.e., those who cannot tolerate lobectomy, but are candidates for sublobar resection), the appropriateness of potential alternatives [e.g., SBRT; ablation] to surgery is an active area of investigation. In the absence of completed randomized phase III trials, the approach to comparing outcomes between surgery, SBRT, or ablative therapies by their efficacy or equivalence is complex. An overview of the role of SBRT and other non-surgical modalities in the management of early-stage lung cancer is the subject of the present review. Full article
(This article belongs to the Special Issue Early-Stage and Operable Non-Small Cell Lung Cancer Treatment: Current Practice and Future Perspectives)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop